Please login to the form below

Not currently logged in
Email:
Password:

Promacta

This page shows the latest Promacta news and features for those working in and with pharma, biotech and healthcare.

Novartis’ Promacta receives US breakthrough therapy designation

Novartis’ Promacta receives US breakthrough therapy designation

Novartis’ Promacta receives US breakthrough therapy designation. Regulatory filings of the rare blood disorder treatment are expected this year. ... Regulatory filings for a first-line indication in the US and Europe are expected to be made for Promacta

Latest news

  • Novartis bags EU approvals for three ex-GSK drugs Novartis bags EU approvals for three ex-GSK drugs

    Revolade - sold as Promacta in the US - has previously been approved to treat the rare disorder chronic immune thrombocytopenia (ITP) in Europe and is also authorised for both ITP and SAA ... Promacta is one of the products from the GSK transaction that

  • Novartis aims to lead immuno-oncology category Novartis aims to lead immuno-oncology category

    The recent acquisition of cancer drugs from GlaxoSmithKline - which included Votrient (pazopanib), Tafinlar (dabrafenib), Mekinist (trametinib) and Promacta (eltrombopag) - added to its portfolio of targeted cancer therapies that can be combined

  • Novartis gets FDA nod for rare blood disorder drug Novartis gets FDA nod for rare blood disorder drug

    Novartis gets FDA nod for rare blood disorder drug. Promacta will provide a treatment option for children over 6 years old. ... The FDA has approved Novartis' Promacta for the treatment of children over six with chronic immune thrombocytopenia (ITP),

  • GSK files Promacta for anaemia indication in US GSK files Promacta for anaemia indication in US

    GSK files Promacta for anaemia indication in US. FDA will review drug under ‘ breakthrough’ designation. ... GSK developed the drug with partners Ligand, which receives royalties on Promacta sales.

  • FDA deems GSK anaemia drug a 'breakthrough' FDA deems GSK anaemia drug a 'breakthrough'

    FDA deems GSK anaemia drug a 'breakthrough'. US regulator will accelerate review of Promacta. ... GSK developed the drug with partners Ligand, which receives royalties on Promacta sales.

More from news
Approximately 6 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    Additional GSK products include the VEGFR inhibitor, Votrient (renal cell carcinoma), Tykerb (HER2 metastatic breast cancer), Arzerra (chronic lymphocytic leukaemia) and Promacta (thrombocytopenia).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

At Pegasus, we specialise in helping deliver healthy messages through integrated communication programmes. In fact, inspiring healthy decisions is all...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics